Life SciencesLiability

TL;DR

Five cyber insurance program structures for CLIA-certified clinical and diagnostic labs in 2026. Sizing depends on specimen volume, PHI sensitivity, and regulatory framework - not on lab headcount or revenue. Ransomware operational interruption is the single biggest claim category and most generalist programs under-cover it.

Best of 2026

Best Diagnostic Lab Cyber Insurance Programs 2026.

Cyber liability sizing for CLIA-certified labs is driven by specimen volume, PHI sensitivity, and regulatory framework. Below are the five program structures we see in 2026, with the structural drivers and what moves premium for each.

  1. 01

    High-volume hospital reference lab

    CLIA-certified labs processing 50,000+ specimens monthly through hospital reference-lab service agreements.

    • - Cyber at $25M-$50M first-party and third-party, sized to annual specimen volume.
    • - HHS OCR breach response and regulatory defense.
    • - Ransomware operational interruption coverage; specimen-processing downtime drives daily revenue loss.
    • - Hospital additional insured for breach notification.
    • - Contingent business interruption for LIS, middleware, and EHR integration vendor failures.
    • - Result-reporting accuracy E&O coverage layered alongside cyber.

    What drives premium: Annual specimen volume, the number of hospital interfaces into the LIS, and the downtime a ransomware event would cause across client hospitals.

  2. 02

    Molecular diagnostic lab

    Labs running PCR, NGS, oncology profiling, and infectious disease molecular tests, often with high-value specialty kits.

    • - Cyber at $10M-$25M sized to PHI volume and genomic data sensitivity.
    • - Professional liability for diagnostic accuracy at $5M-$10M.
    • - Specialty products liability for test kit components and reagents.
    • - CAP accreditation defense.
    • - Specific endorsement for genomic data breach (federal GINA and state-level genetic privacy statutes).
    • - Cloud platform contingent coverage for bioinformatics pipelines.

    What drives premium: Volume and sensitivity of genomic data held, the state genetic privacy statutes that apply, and data retention practices.

  3. 03

    Anatomic pathology lab

    Labs performing histology, immunohistochemistry, cytopathology, and surgical pathology interpretation.

    • - Cyber at $5M-$15M sized to image archive size.
    • - Professional liability for diagnostic accuracy at $5M-$10M (most pathology claim severity is here).
    • - Digital pathology platform vendor contingent coverage.
    • - Specimen handling and storage liability.
    • - CAP accreditation defense.
    • - Telepathology jurisdictional defense for cross-state interpretation.

    What drives premium: Size of the digital image archive, diagnostic accuracy claim history, and how pathology systems connect to referring practices.

  4. 04

    Bioanalytical contract lab (sponsor work)

    GLP-regulated bioanalytical labs supporting pharmaceutical sponsors with PK/PD, immunogenicity, and biomarker testing.

    • - Cyber at $5M-$15M sized to sponsor proprietary data and IP exposure.
    • - Professional liability for assay accuracy and regulatory submission impact.
    • - cGLP-aligned property and validation loss extension.
    • - Sponsor MSA insurance schedule compliance with explicit IP/CDA breach coverage.
    • - No HIPAA exposure if data is de-identified sponsor scope.
    • - Trade secret protection for sponsor proprietary assays.

    What drives premium: Volume of sponsor-confidential study data and IP held, and the data security terms sponsors write into their agreements.

  5. 05

    LDT specialty lab

    Labs offering laboratory-developed tests under the FDA LDT framework, including unique proprietary assays and direct-to-consumer pathways.

    • - Cyber at $10M-$30M sized to direct-to-consumer or B2B platform scope.
    • - Professional liability for diagnostic accuracy with explicit LDT regulatory framework exposure.
    • - FDA LDT regulatory defense coverage (the framework is now actively enforced).
    • - Products liability for kit components and downstream clinical decisions.
    • - Cyber endorsement for AI/ML model-driven clinical decision risk.
    • - D&O if private equity or venture-backed.

    What drives premium: Platform scope, whether results go direct to consumers, and the patient data volume moving through the ordering and reporting platform.

Need a cyber review

A specialist will reach out by end of business day.

Request a coverage review